Business Wire

ADVA

4.6.2020 09:02:08 CEST | Business Wire | Press release

Share
ADVA launches industry’s first ePRC optical cesium clock solution

ADVA (FSE: ADV) today launched the industry’s first ePRC optical cesium atomic clock solution, protecting synchronization networks from costly and dangerous interruptions to satellite signals. The Oscilloquartz OSA 3350 ePRC+ provides unprecedented stability and significantly longer lifetime compared to all other ePRC cesium clocks. It’s also the first cesium clock on the market with built-in SNMP support. This innovation in the design of atomic clocks comes at a critical time when GNSS outages caused by jamming and spoofing attacks are on the rise. Long GNSS disruptions can cause severe network outages and so the OSA 3350 ePRC+ offers vital backup for mission-critical infrastructures that depend on satellite-based timing, such as mobile networks and power utilities. The OSA 3350 ePRC+ also meets the stringent performance demands as well as the cost points needed for mobile networks transitioning to 5G.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005036/en/

“Our OSA 3350 ePRC+ is a truly unique achievement and its importance to the industry can’t be overstated. It arrives at a crucial time with operators seeking an efficient way to deliver highly accurate, ultra-stable frequency and phase synchronization with significantly longer lifetime than existing cesium clocks. Now they can mitigate GNSS vulnerabilities by harnessing market-leading holdover performance for the most robust backup available,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Creating a viable commercial optical atomic clock has been a key mission for a long time. By achieving it, we’re making sure that communication service providers never again have to compromise between performance and lifetime. And, with a frequency stability that outperforms current ITU-T ePRC G.811.1 standards, our OSA 3350 ePRC+ provides the safety net needed for 5G networks.”

Featuring an all-digital design, the OSA 3350 ePRC+ leverages optical-pumping techniques. It greatly improves performance by providing an extremely stable frequency source. When used with enhanced primary reference time clocks (ePRTCs), the OSA 3350 ePRC+ delivers holdover for 14 days with an accumulated error of up to 35 nanoseconds. This far exceeds the ITU-T ePRC G.811.1 standard that requires an accumulated error under 70 nanoseconds. The OSA 3350 ePRC+ also delivers optimum stability for over 10 years, which is 100% longer than the lifespan of high-performance magnetic cesium clocks. With a fully modular design, the optical cesium solution features a wide range of telecom synchronization output interfaces and supports modern and secured management capabilities with SNMP. What’s more, the RoHS-compliant device is fully integrated into ADVA’s Ensemble management and control software suite for operational simplicity and ease of use.

“With our OSA 3350 ePRC+, we’re providing a critical component of tomorrow’s network synchronization. For decades, engineers have focused on maximizing the performance of magnetic cesium clocks despite their limitations. Now we’re opening up a new chapter in the history of time and frequency delivery with a technology that optimizes both performance and lifetime,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “The incredible stability and accuracy that our OSA 3350 ePRC+ generates will bring essential improvements needed for 5G and other critical infrastructures deriving timing from GNSS. At a time when jamming and spoofing attacks are increasing in frequency and duration, it offers vital backup to satellite-based timing. Our OSA 3350 ePRC+ is also fully integrated into our Ensemble network management software suite with built-in SNMP. It couldn’t be easier to monitor the health of the device and perform software upgrades remotely at the touch of the button.”

Watch this product video for more information: https://youtu.be/8jk4y6kH0Ug .

A supporting application video is available here: https://youtu.be/VarsNZNQB9w .

Further details can also be found in these slides: https://adva.li/osa-3350-slides .

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye